Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives.
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation to develop medicines that address critical health problems. The Senior Medical Director, IRF5 Program will serve as the clinical lead for one or more indications within Kymera’s IRF5 clinical development program.
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives.
Kymera Therapeutics